Antidiabetics Market

Antidiabetics Market Size By Product Type (Insulin, Biguanides, GLP-Agonists, Thiazolidinediones, Sulphonylureas, SGLT-2, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and Meglitinides), By Application (Type I Diabetes and Type II Diabetes), Regions, Global Industry Analysis, Share, Growth, Trends, and Forecast 2023 to 2032

Base Year: 2022 Historical Data: 2019-21
  • Report ID: TBI-13569
  • Published Date: Jul, 2023
  • Pages: 236
  • Category: Healthcare
  • Format: PDF
Buy @ $4700.00 Request Sample PDF

The global antidiabetics market was valued at USD 56.0 billion in 2022, growing at a CAGR of 9.9% from 2023 to 2032. The market is expected to reach USD 143.9 billion by 2032. Demand for insulin and oral hypoglycemic drugs is anticipated to be significantly influenced by the rising prevalence of diabetes (Type I and Type II) worldwide. Global diabetes prevalence is predicted to rise from 366 million cases in 2011 to 552 million cases by 2030, according to estimates from the International Diabetes Federation. This rapid rise in prevalence is predicted to significantly impact the growth of the antidiabetics market during the forecast period.

Market Introduction:

Diabetes is a condition when the blood insulin level is unusually high. Diabetes medications treat diabetes mellitus by bringing down blood glucose levels. A lack of insulin brings on Type 1 diabetes, but Type 2 diabetes is brought on by cells resistant to insulin. Approving brand-new diabetic medications like canagliflozin and dapagliflozin would open up a wide range of prospects for new and seasoned competitors. The primary drivers of the growth of the global antidiabetics market over the forecast period are the rising diabetic population, technological advancements, and rising acceptance rates in developing areas. A significant global trend involves a variety of projects designed to offer patients affordable access to insulin and other anti-diabetic medications by developing sophisticated healthcare reimbursement networks. In addition, it is anticipated that introducing new, high-efficiency goods will spur growth. Developing goods like ultra-long-lasting SGLT-2 inhibitor analogues, quick and long-acting insulin analogues with better efficacies, and oral diabetes medications should help the business grow even further. The introduction of improved insulin pen technology, which makes it easy to inject insulin daily with little discomfort, should also drive therapeutic sales.

Antidiabetics Market Size

Get an overview of this study by requesting a free sample

Recent Development

In March 2022, Oramed reported that ORMD-0801, a novel molecule, was tested in two pivotal Phase 3 trials and may one day serve as the first and most practical oral insulin capsule for administering insulin therapy. This medication is anticipated to revolutionize oral anti-diabetes and insulin markets. An oral GLP-1 (glucagon-like peptide-1) analogue capsule (ORMD-0901) is also being developed by Oramed.

Sanofi established a €3 million Planet Mobilisation fund in June 2021 to support further staff initiatives to improve the environment. Three Sanofi teams will have their projects funded this year.

For individuals with Type 2 diabetes, Glenmark Pharmaceuticals Limited announced in July 2022 that sitagliptin and its Fixed Dose Combinations (FDCs) were now offered in India. Glenmark offered eight different sitagliptin-based drug combinations under the trade name SITAZIT and its derivatives for a fair price.

Novo Nordisk announced in February 2020 that ESPEROCT® [antihemophilic factor (recombinant), glycopegylated-exei] is currently available in the United States for the treatment of adults and children with haemophilia A. In persons with haemophilia A, recombinant extended half-life factor VIII replacement therapy known as ESPEROCT® is used to prevent or reduce the number of bleeding episodes, treat and stop bleeding, and manage bleeding during surgery. With less frequent doses, ESPEROCT® can help minimize the frequency of bleeding when taken by mature adults every four days.

Market Dynamics:

Drivers

Surging Applications- A class of drugs known as alpha-glucosidase inhibitors (AGI) is used to treat type 2 diabetes mellitus alone or in combination with other anti-diabetic drugs. They can also prevent type 2 diabetes mellitus from developing in patients with impaired glucose tolerance. They are efficient for patients who run the danger of hypoglycemia or lactic acidosis. AGIs are recommended by the U.S. Food and Drug Administration (FDA) for managing type 2 diabetes mellitus. Although the FDA has not approved them for type 1 diabetes mellitus or gestational diabetes mellitus, they have shown some advantages in these conditions. AGIs help reduce postprandial hyperglycemia in particular. They moderately lower postprandial insulin concentration and glycosylated haemoglobin levels.

Restraints:

Increasing Predominance- A class of drugs known as alpha-glucosidase inhibitors (AGI) is used to treat type 2 diabetes mellitus on its own or in combination with other anti-diabetic drugs. They can also prevent type 2 diabetes mellitus from developing in patients with impaired glucose tolerance. They are efficient for patients who run the danger of hypoglycemia or lactic acidosis. AGIs are recommended by the U.S. Food and Drug Administration (FDA) for managing type 2 diabetes mellitus. Although the FDA has not approved them for type 1 diabetes mellitus or gestational diabetes mellitus, they have shown some advantages in these conditions. AGIs help reduce postprandial hyperglycemia in particular. They moderately lower postprandial insulin concentration and glycosylated haemoglobin levels.

Opportunities:

Rising Cases of Diabetes- According to the World Health Organisation (WHO), there were 108 million cases of diabetes in 1980 and 422 million cases in 2014. In 2019, diabetes was the ninth leading cause of death, accounting for over 1.5 million deaths directly related to the disease. According to more recent WHO reports, Type 2 diabetes, also known as non-insulin-dependent or adult-onset diabetes, is caused by the body's ineffective use of insulin, affecting more than 95% of persons with diabetes. The leading causes of this type of diabetes are being overweight and physically inactive. Several diabetes medications, including metformin, sulphonylureas, glitazones, glides, and alpha-glucosidase inhibitors, are prescribed for Type 2 diabetes.

Regional segmentation analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. Asia Pacific emerged as the most significant global antidiabetics market, with a 55% market revenue share in 2022.

In 2021, 206 million adults in the IDF Western Pacific Region and 90 million individuals in the IDF South-East Asia Region were estimated to have diabetes, respectively. By 2030, this number is projected to rise to 113 million and 238 million. The increased usage of oral anti-diabetic medications is because newer oral medications, like SGLT-2 and DPP-4, lower the rate of CV risk in diabetes patients. As the number of people with diabetes rises, China and Japan are seen as potential rising markets in Asia-Pacific. In addition to weak economic development, an ageing population, and growing competition, Japan is a mature market with these issues. The number of generic medicine producers in the nation is significantly rising.

In July 2022, Glenmark Pharmaceuticals Limited declared sitagliptin and its Fixed Dose Combinations (FDCs) were now available in India for adults with Type 2 diabetes. Under the brand name SITAZIT and its variations, Glenmark made available eight alternative combinations of sitagliptin-based medications for a reasonable price.

Asia Pacific Region Antidiabetics Market Share in 2022 - 55%

 

www.thebrainyinsights.com

Check the geographical analysis of this market by requesting a free sample

Product Type Segment Analysis

The product type segment is divided into insulin, biguanides, GLP-agonists, thiazolidinediones, sulphonylureas, SGLT-2, alpha-glucosidase inhibitors, DPP-4 inhibitors, and meglitinides. The insulin segment dominated, with a market share of around 32% in 2022. The product's high usage rates and potent therapeutic effects influence its market share. Additionally, this segment is anticipated to increase its revenue share throughout the forecast period due to the launch of new products and the potential commercialization of items presently in development. Rapid-acting, long-acting, premixed insulin, premixed analogue, short-acting, and intermediate-acting insulin are all included in the insulin section.

Application Segment Analysis

The application segment is divided into Type I diabetes and Type II diabetes. The Type II diabetes segment dominated the market, with a share of around 58% in 2022. The rising number of people with Type II diabetes in the world is what is causing this growth. Treatment for Type II Diabetes involves the alpha-glucosidase inhibitor. The risk of Type II Diabetes increases beyond the age of 45. The prevalence of obesity and a family history of diabetes further fuel this market's expansion.

Some of the Key Market Players:
  • Sanofi-Aventis
  • Takeda Pharmaceuticals
  • Eli Lilly
  • Oramed Pharmaceuticals
  • Boehringer Ingelheim
  • Merck & Co. Inc.
  • Novo Nordisk
  • Bristol-Myers Squibb
  • Halozyme Therapeutics
  • Pfizer

Report Description:

Attribute Description
Market Size Revenue (USD Billion)
Market size value in 2022 USD 56.0 Billion
Market size value in 2032 USD 143.9 Billion
CAGR (2023 to 2032) 9.9%
Historical data 2019-2021
Base Year 2022
Forecast 2023-2032
Region The regions analyzed for the market are Asia Pacific, Europe, South America, North America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level.
Segments Product Type, Application

Frequesntly Asked Questions

As per The Brainy Insights, the size of the antidiabetics market was valued at USD 56.0 billion in 2022 to USD 143.9 billion by 2032.

The global antidiabetics market is growing at a CAGR of 9.9% during the forecast period 2023-2032.

Asia Pacific emerged as the largest antidiabetics market.

Key players in the antidiabetics market are Sanofi-Aventis, Takeda Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals, Boehringer Ingelheim, Merck & Co. Inc., Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics, and Pfizer.

1. Introduction
    1.1. Objectives of the Study
    1.2. Market Definition
    1.3. Research Scope
    1.4. Currency
    1.5. Key Target Audience

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
    4.1. Porter’s Five Forces Analysis
    4.2. Value Chain Analysis
    4.3. Top Investment Pockets
          4.3.1. Market Attractiveness Analysis by Product Type
          4.3.2. Market Attractiveness Analysis by Application
          4.3.3. Market Attractiveness Analysis by Region
    4.4. Industry Trends

5. Market Dynamics
    5.1. Market Evaluation
    5.2. Drivers
          5.2.1. Surging applications
    5.3. Restraints
          5.3.1. Increasing predominance
    5.4. Opportunities
          5.4.1. Rising cases of diabetes
    5.5. Challenges
          5.5.1. High cost

6. Global Antidiabetics Market Analysis and Forecast, By Product Type
    6.1. Segment Overview
    6.2. Insulin
    6.3. Biguanides
    6.4. GLP-Agonists
    6.5. Thiazolidinediones
    6.6. Sulphonylureas
    6.7. SGLT-2
    6.8. Alpha-Glucosidase Inhibitors
    6.9. DPP-4 Inhibitors
    6.10. Meglitinides

7. Global Antidiabetics Market Analysis and Forecast, By Application
    7.1. Segment Overview
    7.2. Type I Diabetes
    7.3. Type II Diabetes

8. Global Antidiabetics Market Analysis and Forecast, By Regional Analysis
    8.1. Segment Overview
    8.2. North America
          8.2.1. U.S.
          8.2.2. Canada
          8.2.3. Mexico
    8.3. Europe
          8.3.1. Germany
          8.3.2. France
          8.3.3. U.K.
          8.3.4. Italy
          8.3.5. Spain
    8.4. Asia-Pacific
          8.4.1. Japan
          8.4.2. China
          8.4.3. India
    8.5. South America
          8.5.1. Brazil
    8.6. Middle East and Africa
          8.6.1. UAE
          8.6.2. South Africa

9. Global Antidiabetics Market-Competitive Landscape
    9.1. Overview
    9.2. Market Share of Key Players in Global Antidiabetics Market
          9.2.1. Global Company Market Share
          9.2.2. North America Company Market Share
          9.2.3. Europe Company Market Share
          9.2.4. APAC Company Market Share
    9.3. Competitive Situations and Trends
          9.3.1. Product Launches and Developments
          9.3.2. Partnerships, Collaborations, and Agreements
          9.3.3. Mergers & Acquisitions
          9.3.4. Expansions

10. Company Profiles
    10.1. Sanofi-Aventis
          10.1.1. Business Overview
          10.1.2. Company Snapshot
          10.1.3. Company Market Share Analysis
          10.1.4. Company Product Portfolio
          10.1.5. Recent Developments
          10.1.6. SWOT Analysis
    10.2. Takeda Pharmaceuticals
          10.2.1. Business Overview
          10.2.2. Company Snapshot
          10.2.3. Company Market Share Analysis
          10.2.4. Company Product Portfolio
          10.2.5. Recent Developments
          10.2.6. SWOT Analysis
    10.3. Eli Lilly
          10.3.1. Business Overview
          10.3.2. Company Snapshot
          10.3.3. Company Market Share Analysis
          10.3.4. Company Product Portfolio
          10.3.5. Recent Developments
          10.3.6. SWOT Analysis
    10.4. Oramed Pharmaceuticals
          10.4.1. Business Overview
          10.4.2. Company Snapshot
          10.4.3. Company Market Share Analysis
          10.4.4. Company Product Portfolio
          10.4.5. Recent Developments
          10.4.6. SWOT Analysis
    10.5. Boehringer Ingelheim
          10.5.1. Business Overview
          10.5.2. Company Snapshot
          10.5.3. Company Market Share Analysis
          10.5.4. Company Product Portfolio
          10.5.5. Recent Developments
          10.5.6. SWOT Analysis
    10.6. Merck & Co. Inc.
          10.6.1. Business Overview
          10.6.2. Company Snapshot
          10.6.3. Company Market Share Analysis
          10.6.4. Company Product Portfolio
          10.6.5. Recent Developments
          10.6.6. SWOT Analysis
    10.7. Novo Nordisk
          10.7.1. Business Overview
          10.7.2. Company Snapshot
          10.7.3. Company Market Share Analysis
          10.7.4. Company Product Portfolio
          10.7.5. Recent Developments
          10.7.6. SWOT Analysis
    10.8. Bristol-Myers Squibb
          10.8.1. Business Overview
          10.8.2. Company Snapshot
          10.8.3. Company Market Share Analysis
          10.8.4. Company Product Portfolio
          10.8.5. Recent Developments
          10.8.6. SWOT Analysis
    10.9. Halozyme Therapeutics
          10.9.1. Business Overview
          10.9.2. Company Snapshot
          10.9.3. Company Market Share Analysis
          10.9.4. Company Product Portfolio
          10.9.5. Recent Developments
          10.9.6. SWOT Analysis
    10.10. Pfizer
          10.10.1. Business Overview
          10.10.2. Company Snapshot
          10.10.3. Company Market Share Analysis
          10.10.4. Company Product Portfolio
          10.10.5. Recent Developments
          10.10.6. SWOT Analysis

List of Table

1. Global Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

2. Global Insulin, Antidiabetics Market, By Region, 2019-2032 (USD Billion) 

3. Global Biguanides, Antidiabetics Market, By Region, 2019-2032 (USD Billion) 

4. Global GLP-Agonists, Antidiabetics Market, By Region, 2019-2032 (USD Billion) 

5. Global Thiazolidinediones, Antidiabetics Market, By Region, 2019-2032 (USD Billion)

6. Global Sulphonylureas, Antidiabetics Market, By Region, 2019-2032 (USD Billion)

7. Global SGLT-2, Antidiabetics Market, By Region, 2019-2032 (USD Billion)

8. Global Alpha-Glucosidase Inhibitors, Antidiabetics Market, By Region, 2019-2032 (USD Billion)

9. Global DPP-4 Inhibitors, Antidiabetics Market, By Region, 2019-2032 (USD Billion)

10. Global Meglitinides, Antidiabetics Market, By Region, 2019-2032 (USD Billion)

11. Global Antidiabetics Market, By Application, 2019-2032 (USD Billion)

12. Global Type I Diabetes, Antidiabetics Market, By Region, 2019-2032 (USD Billion)

13. Global Type II Diabetes, Antidiabetics Market, By Region, 2019-2032 (USD Billion)

14. North America Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

15. North America Antidiabetics Market, By Application, 2019-2032 (USD Billion)

16. U.S. Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

17. U.S. Antidiabetics Market, By Application, 2019-2032 (USD Billion)

18. Canada Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

19. Canada Antidiabetics Market, By Application, 2019-2032 (USD Billion)

20. Mexico Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

21. Mexico Antidiabetics Market, By Application, 2019-2032 (USD Billion)

22. Europe Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

23. Europe Antidiabetics Market, By Application, 2019-2032 (USD Billion)

24. Germany Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

25. Germany Antidiabetics Market, By Application, 2019-2032 (USD Billion)

26. France Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

27. France Antidiabetics Market, By Application, 2019-2032 (USD Billion)

28. U.K. Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

29. U.K. Antidiabetics Market, By Application, 2019-2032 (USD Billion)

30. Italy Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

31. Italy Antidiabetics Market, By Application, 2019-2032 (USD Billion)

32. Spain Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

33. Spain Antidiabetics Market, By Application, 2019-2032 (USD Billion)

34. Asia Pacific Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

35. Asia Pacific Antidiabetics Market, By Application, 2019-2032 (USD Billion)

36. Japan Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

37. Japan Antidiabetics Market, By Application, 2019-2032 (USD Billion)

38. China Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

39. China Antidiabetics Market, By Application, 2019-2032 (USD Billion)

40. India Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

41. India Antidiabetics Market, By Application, 2019-2032 (USD Billion)

42. South America Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

43. South America Antidiabetics Market, By Application, 2019-2032 (USD Billion)

44. Brazil Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

45. Brazil Antidiabetics Market, By Application, 2019-2032 (USD Billion)

46. Middle East and Africa Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

47. Middle East and Africa Antidiabetics Market, By Application, 2019-2032 (USD Billion)

48. UAE Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

49. UAE Antidiabetics Market, By Application, 2019-2032 (USD Billion)

50. South Africa Antidiabetics Market, By Product Type, 2019-2032 (USD Billion)

51. South Africa Antidiabetics Market, By Application, 2019-2032 (USD Billion)

List of Figures 

1. Global Antidiabetics Market Segmentation

2. Global Antidiabetics Market: Research Methodology

3. Market Size Estimation Methodology: Bottom-Up Approach

4. Market Size Estimation Methodology: Top-Down Approach

5. Data Triangulation

6. Porter’s Five Forces Analysis 

7. Value Chain Analysis 

8. Global Antidiabetics Market Attractiveness Analysis by Product Type

9. Global Antidiabetics Market Attractiveness Analysis by Application

10. Global Antidiabetics Market Attractiveness Analysis by Region

11. Global Antidiabetics Market: Dynamics

12. Global Antidiabetics Market Share by Product Type (2023 & 2032)

13. Global Antidiabetics Market Share by Application (2023 & 2032)

14. Global Antidiabetics Market Share by Regions (2023 & 2032)

15. Global Antidiabetics Market Share by Company (2022)

This study forecasts global, regional, and country revenue from 2019 to 2032. The Brainy Insights has segmented the global antidiabetics market based on the below-mentioned segments:

Global Antidiabetics Market By Product Type:

  • Insulin
  • Biguanides
  • GLP-Agonists
  • Thiazolidinediones
  • Sulphonylureas
  • SGLT-2
  • Alpha-Glucosidase Inhibitors
  • DPP-4 Inhibitors
  • Meglitinides

Global Antidiabetics Market By Application:

  • Type I Diabetes
  • Type II Diabetes

Global Antidiabetics Market By Region:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
  • Asia-Pacific
    • Japan
    • China
    • India
  • South America
    • Brazil
  • Middle East and Africa  
    • UAE
    • South Africa

Methodology

Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision. 

Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.

The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.

Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:

MARKET RESEARCH PROCESS

Data Procurement:

The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.

The data procurement stage involves in data gathering and collecting through various data sources.

This stage involves in extensive research. These data sources includes:

Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:

  • The organizational databases such as D&B Hoovers, and Bloomberg that helps us to identify the competitive scenario of the key market players/organizations along with the financial information.
  • Industry/Market databases such as Statista, and Factiva provides market/industry insights and deduce certain formulations. 
  • We also have contractual agreements with various reputed data providers and third party vendors who provide information which are not limited to:
    • Import & Export Data
    • Business Trade Information
    • Usage rates of a particular product/service on certain demographics mainly focusing on the unmet prerequisites

Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.

Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.

The supply side for a domain specific market is analysed by:

  • Estimating and projecting penetration rates through analysing product attributes, availability of internal and external substitutes, followed by pricing analysis of the product.
  • Experiential assessment of year-on-year sales of the product by conducting interviews.

The demand side for the market is estimated through:

  • Evaluating the penetration level and usage rates of the product.
  • Referring to the historical data to determine the growth rate and evaluate the industry trends

In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.

Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:

  • Applying demographic along with psychographic segmentation for market evaluation
  • Determining the Micro and Macro-economic indicators for each region 
  • Examining the industry indicators prevailing in the market. 

Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:

  • Data Screening: Data screening is the process of scrutinising data/information collected from primary research for errors and amending those collected data before data integration method. The screening involves in examining raw data, identifying errors and dealing with missing data. The purpose of the data screening is to ensure data is correctly entered or not. The Brainy Insights employs objective and systematic data screening grades involving repeated cycles of quality checks, screening and suspect analysis.
  • Data Integration: Integrating multiple data streams is necessary to produce research studies that provide in-depth picture to the clients. These data streams come from multiple research studies and our in house database. After screening of the data, our analysts conduct creative integration of data sets, optimizing connections between integrated surveys and syndicated data sources. There are mainly 2 research approaches that we follow in order to integrate our data; top down approach and bottom up approach.

Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.

This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.

Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.

The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:

  • CXOs and VPs of leading companies’ specific to sector
  • Purchasing managers, technical personnel, end-users
  • Key opinion leaders such as investment bankers, and industry consultants

Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.

Some Facts About The Brainy Insights

50%

Free Customization

300+

Fortune 500 Clients

1

Free Yearly Update On Purchase Of Multi/Corporate License

900+

Companies Served Till Date